Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30205928 | 0.95 | CCNC (0.34) | CCNCCDK8ADORA3TSHRMC4R | |
| Formic Acid SCHEMBL30206230 | 0.95 | CCNC (0.34) | CCNCCDK8ADORA3TSHRMC4R | |
| SCHEMBL30206345 | 0.88 | EGLN1 (0.34) | CCNCCDK8CHEK1 | |
| SCHEMBL30802785 | 0.78 | IKBKB (0.33) | CCNCCDK8 | |
| SCHEMBL29173574 | 0.78 | IKBKB (0.37) | — | |
| SCHEMBL29173707 | 0.78 | IKBKB (0.33) | CCNCCDK8 | |
| SCHEMBL31195427 | 0.77 | DGAT1 (0.38) | CCNCCDK8DGAT1 | |
| Formic Acid SCHEMBL30206200 | 0.75 | IKBKB (0.31) | CCNCCDK8 | |
| SCHEMBL30206118 | 0.74 | EGLN1 (0.38) | TSHR | |
| SCHEMBL21722435 | 0.73 | DYRK1A (0.50) | DGAT1MAP3K14TGFBR1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |